Baohui Xu Selected Research

Pancreatic Elastase (Elastase)

11/2023	The incidence rate and histological characteristics of intimal hyperplasia in elastase-induced experimental abdominal aortic aneurysms in mice.
1/2022	Kunming mouse strain is less susceptible to elastase-induced abdominal aortic aneurysms.
1/2021	Recombinant Interleukin-19 Suppresses the Formation and Progression of Experimental Abdominal Aortic Aneurysms.
1/2021	No Effect of Hypercholesterolemia on Elastase-Induced Experimental Abdominal Aortic Aneurysm Progression.
1/2019	Inhibition of VEGF (Vascular Endothelial Growth Factor)-A or its Receptor Activity Suppresses Experimental Aneurysm Progression in the Aortic Elastase Infusion Model.
4/2013	Peptide inhibitor of CXCL4-CCL5 heterodimer formation, MKEY, inhibits experimental aortic aneurysm initiation and progression.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Baohui Xu Research Topics

Disease

25	Abdominal Aortic Aneurysm 11/2023 - 01/2012
12	Aneurysm (Aneurysms) 01/2023 - 01/2012
8	Inflammation (Inflammations) 01/2023 - 09/2004
7	Stroke (Strokes) 10/2022 - 07/2012
6	Ischemic Stroke 01/2023 - 01/2020
5	Aortic Aneurysm (Aneurysm, Aortic) 01/2023 - 01/2012
4	Infarction (Infarctions) 10/2022 - 07/2012
4	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 05/2014 - 11/2005
4	Contact Dermatitis (Eczema, Contact) 11/2007 - 10/2002
3	Hyperplasia 04/2024 - 01/2017
3	Brain Ischemia (Cerebral Ischemia) 01/2023 - 01/2019
3	Brain Injuries (Brain Injury) 01/2023 - 01/2016
3	Body Weight (Weight, Body) 01/2023 - 01/2016
3	Hypertension (High Blood Pressure) 01/2023 - 01/2022
3	Atherosclerosis 10/2022 - 01/2016
3	Neoplasms (Cancer) 08/2022 - 10/2009
3	Hypoxia (Hypoxemia) 01/2022 - 11/2021
3	Coronary Artery Disease (Coronary Atherosclerosis) 06/2019 - 08/2016
3	Disease Progression 01/2019 - 01/2012
3	Persistent Infection 07/2014 - 04/2007
3	Infections 07/2014 - 04/2007
2	Reperfusion Injury 10/2022 - 01/2019
2	Immune System Diseases (Immune Disorders) 08/2022 - 11/2007
2	Glioma (Gliomas) 06/2022 - 10/2009
2	Glioblastoma (Glioblastoma Multiforme) 06/2022 - 10/2009
2	Cardiovascular Diseases (Cardiovascular Disease) 01/2022 - 01/2020
2	Autoimmune Diseases (Autoimmune Disease) 11/2021 - 05/2014
2	Neuroinflammatory Diseases 01/2021 - 01/2016
2	Hyperlipidemias (Hyperlipidemia) 01/2021 - 01/2016
2	Rupture 01/2018 - 01/2012
2	Overweight 01/2016 - 01/2016
2	Carcinogenesis 06/2013 - 01/2005
1	Cerebral Infarction 01/2023
1	Ischemia 01/2023
1	Middle Cerebral Artery Infarction (Middle Cerebral Artery Syndrome) 01/2023
1	Peripheral Arterial Disease 01/2023
1	Varicose Veins (Varicose Vein) 01/2023
1	Vascular Diseases (Vascular Disease) 10/2022
1	Brain Edema (Cerebral Edema) 10/2022
1	Colitis 01/2022
1	VLCAD deficiency 01/2022

Drug/Important Bio-Agent (IBA)

6	Pancreatic Elastase (Elastase)IBA 11/2023 - 04/2013
6	Proteins (Proteins, Gene)FDA Link 01/2023 - 09/2004
6	LipidsIBA 01/2023 - 09/2004
6	CytokinesIBA 01/2023 - 06/2007
5	Angiotensin IIIBA 09/2023 - 01/2017
5	Glucose (Dextrose)FDA LinkGeneric 01/2023 - 01/2016
4	Oxygen (Dioxygen)IBA 01/2023 - 01/2022
4	AngiotensinsIBA 11/2021 - 01/2012
3	Member 1 Subfamily B ATP Binding Cassette TransporterIBA 01/2023 - 01/2019
3	Metformin (Glucophage)FDA LinkGeneric 01/2023 - 01/2016
3	Telmisartan (Micardis)FDA Link 06/2022 - 01/2012
3	Peptides (Polypeptides)IBA 01/2022 - 04/2013
3	Messenger RNA (mRNA)IBA 01/2022 - 11/2018
3	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 01/2022 - 11/2018
3	Matrix Metalloproteinase 2 (Gelatinase A)IBA 01/2022 - 11/2018
2	Monoclonal AntibodiesIBA 09/2023 - 10/2009
2	Apolipoproteins E (ApoE)IBA 09/2023 - 01/2012
2	ChemokinesIBA 01/2023 - 06/2007
2	C-Reactive ProteinIBA 01/2023 - 06/2019
2	ApolipoproteinsIBA 01/2023 - 01/2021
2	ReninIBA 01/2023 - 01/2012
2	Small Interfering RNA (siRNA)IBA 10/2022 - 01/2022
2	Caspase 3 (Caspase-3)IBA 01/2022 - 01/2016
2	RNA (Ribonucleic Acid)IBA 01/2022 - 01/2020
2	Fatty Acids (Saturated Fatty Acids)IBA 01/2022 - 01/2016
2	LigandsIBA 11/2021 - 11/2007
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 01/2016
2	AngiotensinogenIBA 06/2019 - 01/2017
2	Phosphotransferases (Kinase)IBA 01/2019 - 01/2016
2	Interferon-gamma (Interferon, gamma)IBA 04/2010 - 04/2007
2	Interleukin-4 (Interleukin 4)IBA 08/2008 - 10/2002
2	DNA (Deoxyribonucleic Acid)IBA 01/2005 - 09/2004
1	urotensin IIIBA 04/2024
1	CollagenIBA 01/2023
1	Glucocorticoid Receptors (Glucocorticoid Receptor)IBA 01/2023
1	Interleukin-6 (Interleukin 6)IBA 01/2023
1	Vasodilator Agents (Vasodilators)IBA 01/2023
1	MicroRNAs (MicroRNA)IBA 01/2023
1	Antihypertensive Agents (Antihypertensives)IBA 01/2023
1	Disulfiram (Antabuse)FDA Link 01/2023
1	Advanced Glycation End ProductsIBA 01/2023
1	Interleukin-12 (IL 12)IBA 01/2023
1	Interferon alpha-beta Receptor (Receptor, Interferon alpha beta)IBA 10/2022
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 10/2022
1	Matrix Metalloproteinases (MMPs)IBA 10/2022
1	Tight Junction ProteinsIBA 10/2022
1	Peroxisome ProliferatorsIBA 06/2022
1	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 06/2022
1	Superoxide Dismutase-1IBA 01/2022
1	lipoprotein cholesterolIBA 01/2022
1	Protein Hydrolysates FDA Link 01/2022
1	dapagliflozinIBA 01/2022
1	Oxidoreductases (Dehydrogenase)IBA 01/2022

Therapy/Procedure

7	Therapeutics 01/2023 - 06/2013
2	Stents 06/2019 - 01/2017
2	Sutures (Suture) 02/2013 - 07/2012
1	Ligation 04/2024
1	Subcutaneous Infusions 01/2023
1	Investigational Therapies (Experimental Therapy) 08/2022